Denmark's C25 Posts Worst Start to 2026 Among Developed Markets, Concentration Risk Laid Bare

• The C25 has underperformed every other developed-market benchmark in early 2026, continuing a pattern from late 2025
• Heavy concentration in pharmaceuticals — particularly Novo Nordisk — leaves the index acutely exposed to US drug-pricing policy
• Swedish, Norwegian, and Finnish indices have held up better, partly due to broader sectoral diversification
• Danish pension funds and Nordic retail investors face real balance-sheet consequences from a sustained C25 slump

Denmark's C25 index has posted the worst start to 2026 of any stock exchange in the developed world. Ekstra Bladet reports that Danish equities are continuing what it calls a "nightmare" — a streak of underperformance that now stretches back months and shows no sign of reversing. The selloff is not a blip. It is the market pricing in structural problems that Copenhagen's political and financial establishment has been slow to acknowledge.

The root cause is concentration. The C25 is not really a twenty-five-company index in any meaningful sense. It is a Novo Nordisk index with decorations. The pharmaceutical giant's weighting means the benchmark moves largely in lockstep with one company's fortunes — and those fortunes are currently under pressure. Washington's intensifying scrutiny of drug pricing, combined with growing bipartisan appetite for restricting pharmaceutical imports and renegotiating market-access terms, hits Denmark's flagship exporter directly. When a single stock can drag an entire national index to the bottom of the global league table, the word "diversified" does not apply.

The broader trade-war environment compounds the problem. Denmark's open, export-dependent economy — pharmaceuticals, wind turbines, agricultural products — is disproportionately exposed to tariff escalation and protectionist policy shifts in its key markets. The Danish krone's peg to the euro, normally a source of stability, becomes a constraint when the central bank cannot independently adjust monetary policy to cushion external shocks. Investors appear to be pricing in the possibility that Denmark absorbs more pain than its Nordic neighbours precisely because it has fewer policy tools available.

The contrast with the rest of the Nordic region is instructive. Sweden's OMX Stockholm 30, while hardly booming, has outperformed the C25 — benefiting from a weaker krona that flatters export earnings and a broader sectoral mix spanning industrials, financials, and technology. Norway's OBX, buoyed by energy prices and a sovereign wealth fund that anchors investor confidence, has likewise held up. Finland's Helsinki exchange, smaller and more cyclical, has still managed to avoid the kind of concentrated drawdown afflicting Copenhagen. The common thread: none of these markets depend on one company to the degree Denmark does.

The consequences extend well beyond trading desks. Danish pension funds — among the largest institutional investors in Europe relative to GDP — hold substantial C25 exposure. ATP, PFA, and the labour-market funds that manage retirement savings for millions of Danes are all affected when the benchmark drops. Nordic retail investors, who increasingly hold Danish equities through cross-border platforms and index funds, are similarly exposed. A sustained C25 slump is not an abstraction; it erodes the household wealth of ordinary savers across the region.

Denmark's political class has spent decades cultivating an image of the country as a stable, well-managed economy — the kind of place where pension returns are reliable and equity markets reward patience. The C25's 2026 performance tells a different story: a market that bet everything on one sector, tied its currency to a monetary policy it cannot control, and now finds itself at the bottom of every developed-market ranking. Novo Nordisk's share price has become, in effect, Denmark's national economic indicator — and right now, the indicator is pointing down.

Sources: Ekstra Bladet